Genentech outlines R&D efforts

06/11/2008 | Wall Street Journal, The

Genentech intends to pursue research in neuroscience and infectious diseases as well as seek new uses for top-selling drugs, a company official said at a health care conference. The firm's Avastin -- on the market to treat breast, colon and lung cancers -- is being studied on people with renal cancer and certain kinds of brain tumors. Genentech also is working on 14 novel molecules to treat different cancers, said Susan Desmond-Hellmann, president of product development.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care